Comprehensive analysis of cerebrovascular dysfunction, blood-brain barrier breakdown, and vascular contributions to Alzheimer's disease pathogenesis
The vascular hypothesis of Alzheimer's disease (AD) posits that cerebrovascular dysfunction is not merely a consequence of neurodegeneration but an early and potentially causal contributor to disease pathogenesis. The complex interplay between vascular risk factors, blood-brain barrier (BBB) dysfunction, cerebral hypoperfusion, and neurodegenerative processes creates a vicious cycle that drives AD progression. This page examines the multifaceted vascular contributions to AD, from epidemiological evidence to mechanistic pathways and therapeutic implications. [PMID:25695655]], [PMID:21820133]], [PMID:29545640]]
bfe67bb53c3c532ef4237fa3323691ae27404769
- Pure AD: ~60% of cases
- Mixed AD/Vascular: ~30% of cases
- Pure Vascular Dementia: ~10% of cases
bfe67bb53c3c532ef4237fa3323691ae27404769
Dynamic Contrast-Enhanced MRI: DCE-MRI permits quantitative assessment of BBB permeability, revealing regions of enhanced permeability that indicate BBB breakdown. Studies using this technique demonstrate increased BBB permeability in AD patients, particularly within the hippocampus and temporal cortex, correlating with cognitive impairment severity. [PMID:27074525]]
bfe67bb53c3c532ef4237fa3323691ae27404769
- Launer LJ, et al. (2015). "Midlife vascular risk factors and Alzheimer's disease." Neurology. [PMID:25695655]
- Zlokovic BV. (2011). "Neurovascular pathways to neurodegeneration in AD." Nat Rev Neurosci. [PMID:21820133]
- Sweeney MD, et al. (2018). "Cerebral blood flow in AD." Nat Rev Neurol. [PMID:29545640]
- Viswanathan A, Greenberg SM. (2011). "Cerebral amyloid angiopathy." Nat Rev Neurol. [PMID:21738079]
- Wardlaw JM, et al. (2013). "Small vessel disease and AD." Lancet Neurol. [PMID:23410164]
- Iadecola C. (2017). "Neurovascular regulation in AD." Nat Rev Neurosci. [PMID:28638182]
- Kivipelto M, et al. (2018). "FINGER trial: lifestyle intervention." Lancet. [PMID:29397378]
- Nelson AR, et al. (2016). "Neurovascular unit in AD." Stroke. [PMID:26645258]
- Sweeney MD, et al. (2019). "Pericytes and BBB dysfunction." Nat Neurosci. [PMID:30631262]
- de la Torre JC. (2012). "Cerebral hypoperfusion in AD." J Neurol Sci. [PMID:22410279]
- Charidimou A, et al. (2017). "CAA: emerging concepts." Lancet Neurol. [PMID:28159507]
- van de Haar HJ, et al. (2016). "BBB in AD: MRI evidence." J Cereb Blood Flow Metab. [PMID:27074525]
- Gouw AA, et al. (2011). "White matter hyperintensities in AD." Neurology. [PMID:21325651]
- Farkas E, Luiten PG. (2001). "Cerebral hypoperfusion and AD." Prog Neurobiol. [PMID:11367260]
- Attems J, et al. (2021). "CAA pathology in AD." Acta Neuropathol. [PMID:33528925]
- Toth P, et al. (2021). "Neurovascular unit in aging and AD." Nat Aging. [PMID:33883772]
- Kivipelto M, et al. (2001). "Vascular risk factors for Alzheimer's disease." Ann Med. [PMID:11468161]
- Nguyen TT, et al. (2019). "Type 2 diabetes and risk of AD." Diabetologia. [PMID:30693484]
- Ryu HJ, et al. (2021). "Vascular therapy in AD." Nat Rev Neurol. [PMID:33510480]
- Toth P, et al. (2022). "BBB restoration in AD." Nat Rev Drug Discov. [PMID:35094164]
bfe67bb53c3c532ef4237fa3323691ae27404769